|0.652|| +0.052 / +8.67%|
Palatin Technologies, Inc. is a biopharmaceutical company which develops targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Its programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Its primary product in development is bremelanotide for the treatment of female sexual dysfunction. It is also developing an inhalation formulation of peptide mimetic natriuretic peptide receptor A-agonist, for treatment of cardiovascular and pulmonary indications. The company was founded by Carl Spana and John K. A. Prendergast on November 21, 1986 and is headquartered in Cranbury, NJ.
|Carl Spana||President, Chief Executive Officer & Director|
|Stephen T. Wills||COO, CFO, Secretary, Treasurer & Executive VP|
|Johna Lucas||Chief Medical Officer|
|Stephen A. Slusher||Chief Legal Officer|